{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-121738","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.153613+00:00","generated_at":"2026-06-07T20:12:19.751311+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"United Therapeutics extends Adcirca license with Lilly through Dec 2026","bullets":["Exclusive US marketing license for Adcirca extended from Dec 31, 2023 to Dec 31, 2026.","Other terms of the license agreement remain unchanged.","Adcirca (tadalafil) is for treatment of pulmonary hypertension in the US."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-121738","json":"https://secwatch.observer/filing/0001104659-23-121738.json","markdown":"https://secwatch.observer/filing/0001104659-23-121738.md","text":"https://secwatch.observer/filing/0001104659-23-121738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000110465923121738/0001104659-23-121738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000110465923121738/tm2323177d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:12:19.751311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}